Correction to: The impact of metformin use on the outcomes of relapse‑remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open‑label randomized controlled trial

Mohamed Y Abdelgaied^{1

2}, Mohamed Hamed Rashad³, Hend M El-Tayebi⁴, Mohamed H Solayman^{5

6}

Affiliations

¹ Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.
² Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
³ Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
⁴ Clinical Pharmacology and Pharmacogenomics Research Group, Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
⁵ Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt. mohamed.solayman@guc.edu.eg.
⁶ Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. mohamed.solayman@guc.edu.eg.

Published Erratum

Mohamed Y Abdelgaied et al. J Neurol. 2024 May.

. 2024 May;271(5):2925.

doi: 10.1007/s00415-024-12249-9.

Mohamed Y Abdelgaied^{1

2}, Mohamed Hamed Rashad³, Hend M El-Tayebi⁴, Mohamed H Solayman^{5

6}

¹ Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.
² Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
³ Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
⁴ Clinical Pharmacology and Pharmacogenomics Research Group, Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
⁵ Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt. mohamed.solayman@guc.edu.eg.
⁶ Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. mohamed.solayman@guc.edu.eg.

No abstract available

Erratum for

The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
Abdelgaied MY, Rashad MH, El-Tayebi HM, Solayman MH. Abdelgaied MY, et al. J Neurol. 2024 Mar;271(3):1124-1132. doi: 10.1007/s00415-023-12113-2. Epub 2023 Dec 9. J Neurol. 2024. PMID: 38070031 Clinical Trial.